Kenneth Kelley

Kenneth J.
Kelley was the founder of IntraBiotics Pharmaceuticals, Inc., founded in 1994, where the title held was Chairman & Chief Executive Officer.
Mr. Kelley was the founder of Emergent Travel Health, Inc., founded in 2007, with the title Chief Executive Officer & Director in 2015.
Mr. Kelley is the founder of IDBiologics, Inc., founded in 2017, holding the title Chief Executive Officer.
Current jobs include Chairman at Seromyx Systems, Inc. and Selva Therapeutics, Inc., Managing Director at K2 BioVentures LLC since 2004, Executive Director at Meissa Vaccines, Inc. since 2019, and Director at Actym Therapeutics, Inc. Former jobs include Executive Chairman at Fluxion Biosciences, Inc., Independent Director at Halozyme Therapeutics, Inc. from 2015 to 2021, Director at Solus Biosystems, Inc. and MPEX Pharmaceuticals, Inc., General Partner at Latterell Venture Partners from 2002 to 2004, Trustee at Albert B. Sabin Vaccine Institute, Inc., Associate at Institutional Venture Partners, Consultant at McKinsey & Co., Inc., and Scientist at Integrated Genetics, Inc. Education includes undergraduate studies at Harvard University and an MBA from Stanford University.